Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study

Leukemia - Tập 32 Số 12 - Trang 2558-2571 - 2018
Jan Braess1, Susanne Amler2, Karl‐Anton Kreuzer3, Karsten Spiekermann4, Hans Walter Lindemann5, Eva Lengfelder6, Ullrich Graeven7, Peter Staib8, Wolfgang Ludwig9, Harald Biersack10, Yon‐Dschun Ko11, M. Uppenkamp12, Maike de Wit13, Stefan Korsten14, Rudolf Peceny15, Tobias Gaska16, Xaver Schiel17, Dirk Behringer18, Michael Kiehl19, Bettina Zinngrebe20, G. Meckenstock21, E. Roemer22, Dirk Medgenberg23, E. Spaeth-Schwalbe24, Gero Massenkeil25, Heidrun Hindahl26, Rainer Schwerdtfeger27, Guido Trenn28, Cristina Sauerland2, Raphael Koch2, Martin Lablans2, Andreas Faldum2, Dennis Görlich2, Stefan K. Bohlander29, Stephanie Schneider4, Annika Dufour4, Christian Buske30, Michael Fiegl4, Marion Subklewe4, Birgit Braess4, Michael Unterhalt4, Anja Baumgartner4, Bernhard Wörmann31, Dietrich W. Beelen32, Wolfgang Hiddemann4
1Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany;
2Insitute for Biostatistics and Clinical Research, University Hospital, Münster, Germany
3Department of Internal Medicine I, University Hospital, Cologne, Germany
4Department of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany
5Department of Hematology and Oncology, Catholic Hospital, Hagen, Germany
6Department of Medicine III, University Hospital Mannheim, Germany
7Department of Medicine I, Hospital Maria Hilf, Mönchengladbach, Germany
8Department of Hematology and Medical Oncology, St. Antonius Hospital, Eschweiler, Germany
9Department of Hematology and Oncology and Tumor Immunology, Helios Hospital, Berlin-Buch, Germany
10Department of Medicine I, University Hospital, Lübeck, Germany
11Department of Medicine I, Johanniter Hospital, Bonn, Germany
12Department of Medicine A, Klinikum Ludwigshafen, Ludwigshafen, Germany
13Department of Hematology, Oncology and Palliative Care, Vivantes Klinikum Neukölln, Berlin, Germany
14Department of Medicine, Vinzenz Pallotti Hospital, Bergisch-Gladbach, Germany
15Department of Hematology and Oncology, Klinikum Osnabrück, Osnabrück, Germany
16Department of Hematology and Oncology, St. Josef Hospital, Paderborn, Germany
17Department of Hematology and Oncology, Klinikum Harlaching, Munich, Germany
18Department of Hematology, Oncology and Palliative Care, Augusta Hospital, Bochum, Germany
19Department of Medicine I, Klinikum Frankfurt/Oder, Frankfurt/Oder, Germany
20Department of Hematology, Oncology and Palliative Care, Evangelisches Krankenhaus, Bielefeld, Germany
21Department of Medical Oncology, Radiooncology, Hematology and Palliative Care, St. Josef Hospital, Gelsenkirchen, Germany
22Department of Hematology and Oncology, Klinikum Idar-Oberstein, Idar-Oberstein, Germany
23Department of Medicine III, Klinikum Leverkusen, Leverkusen, Germany
24Department of Medicine, Vivantes Klinikum Spandau, Berlin, Germany
25Department of Medicine II, Klinikum Gütersloh, Gütersloh, Germany
26Department of Medicine I, St. Johannes Hospital, Dortmund, Germany
27Department for Bone Marrow and Blood Stem Cell Transplantation, DKD Deutsche Klinik für Diagnostik, Wiesbaden, Germany
28Department of Medicine I, Knappschaftskrankenhaus, Bottrop, Germany
29Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
30Institute of Experimental Cancer Research, University Hospital, Ulm, Germany
31German Society of Hematology and Oncology DGHO, Berlin, Germany
32Department of Bone Marrow Transplantation, University Hospital, Essen, Germany

Tóm tắt

Từ khóa


Tài liệu tham khảo

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454–64.

Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Gorlich D, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128:686–98.

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21.

Buchner T, Hiddemann W, Wormann B, Loffler H, Gassmann W, Haferlach T, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93:4116–24.

Buchner T, Krug UO, Peter Gale R, Heinecke A, Sauerland MC, Haferlach C, et al. Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia. Leukemia. 2016;30:1781–4.

Castaigne S, Chevret S, Archimbaud E, Fenaux P, Bordessoule D, Tilly H, et al. Randomized comparison of double induction and timed-sequential induction to a “3+7” induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood. 2004;104:2467–74.

Schaich M, Parmentier S, Kramer M, Illmer T, Stolzel F, Rollig C, et al. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol. 2013;31:2094–102.

Kern W, Schoch C, Haferlach T, Braess J, Unterhalt M, Wormann B. et al. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia. 2000;14:226–31.

Braess J, Spiekermann K, Staib P, Gruneisen A, Wormann B, Ludwig WD, et al. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood. 2009;113:3903–10.

Krug U, Berdel WE, Gale RP, Haferlach C, Schnittger S, Muller-Tidow C, et al. Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. Leukemia. 2016;30:1230–6.

Buchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol. 2006;24:2480–9.

Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642–9.

Whitehead J. The design and analysis of sequential clinical trials. 3rd ed. John Wiley & Sons; 1997.

Kern W, Aul C, Maschmeyer G, Kuse R, Kerkhoff A, Grote-Metke A, et al. Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative Group. Ann Hematol. 1998;77:115–22.

Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, et al. Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. Blood Cancer J. 2017;7:e564.

Woods WG, Kobrinsky N, Buckley JD, Lee JW, Sanders J, Neudorf S, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children’s Cancer Group. Blood. 1996;87:4979–89.

Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001;97:56–62.

Rollig C, Serve H, Huttmann A, Noppeney R, Muller-Tidow C, Krug U, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16:1691–9.

Thông tin
Thông tin xuất bản

Leukemia

Tập 32 Số 12

2558-2571

Thông tin tác giả